Eperisone Dosing
For adults and children 12 years and older, administer eperisone 50 mg three times daily (150 mg/day total), which can be increased to 100 mg three times daily (300 mg/day total) for more severe symptoms. 1
Standard Adult Dosing
The FDA-approved dosing is 2 caplets every 6 hours, not exceeding 8 caplets in 24 hours, with a full glass of water 1. However, clinical research demonstrates more specific regimens:
- Initial dose: 50 mg three times daily (150 mg/day total) 2, 3
- Maximum dose: 100 mg three times daily (300 mg/day total) 4, 3
- Duration: Typically 10-14 days for acute musculoskeletal conditions 2, 3
The 300 mg/day dose shows significantly superior efficacy compared to 150 mg/day, particularly for spastic palsy (p=0.004 for spasticity reduction) and improved walking capability (p<0.05) 4. For acute low back pain with muscle spasm, the 300 mg/day regimen achieved 79.46% good-to-excellent response rates versus 38.05% with placebo 2.
Pediatric Dosing (Under 12 Years)
Do not use eperisone in children under 12 years of age without consulting a physician 1. The FDA label explicitly contraindicates use in this population due to lack of safety and efficacy data, and because of Reye's syndrome risk in children with viral illnesses 1.
Elderly Patients
Use the standard adult dose (150-300 mg/day) in elderly patients, but initiate at the lower end (150 mg/day) and monitor closely for adverse effects. While no specific elderly dosing guidelines exist for eperisone in the available evidence, general geriatric principles apply 5. The drug's rapid elimination (half-life 1.87 hours) and lack of accumulation with repeated dosing 6 suggest lower risk in elderly patients compared to other muscle relaxants. However, common adverse effects including light-headedness, vertigo, loss of equilibrium, and mild somnolence 3 warrant cautious initiation.
Renal Impairment
No dose adjustment is required for mild to moderate renal impairment. Eperisone undergoes rapid elimination with a biological half-life of 1.87 hours and shows no drug accumulation even with repeated dosing 6. The negligible plasma concentrations (0.063-0.067 ng/mL) measured before dosing during steady-state indicate complete elimination between doses 6. Unlike renally-cleared medications that require dose adjustment 7, eperisone's pharmacokinetic profile does not suggest renal accumulation risk.
For severe renal impairment or dialysis patients, no specific data exists in the evidence provided. Apply clinical judgment and consider starting at 150 mg/day.
Hepatic Impairment
No dose adjustment is required for mild to moderate hepatic impairment based on available evidence. Eperisone demonstrates a favorable tolerability profile with minimal hepatic adverse effects reported 2, 3. Only one case of epigastric pain was noted among 100 patients in one study 3, and the drug is not listed among medications requiring hepatic dose adjustment in general reviews 8.
For severe hepatic impairment, no specific data exists. Consider initiating at 150 mg/day and monitoring liver function.
Critical Safety Considerations
Avoid eperisone in children with viral illnesses (chicken pox, flu-like symptoms) due to Reye's syndrome risk 1. This is a critical contraindication that must be screened for in any patient under 18 years.
Screen for hypersensitivity history before prescribing. Eperisone can cause immediate hypersensitivity reactions including anaphylaxis, often misdiagnosed as NSAID hypersensitivity when co-prescribed 9. The incidence of seizures is 2.5% 2, which is clinically significant.
Limit caffeine intake during treatment as eperisone formulations may contain caffeine equivalent to a cup of coffee, potentially causing nervousness, irritability, sleeplessness, and tachycardia 1.
Pharmacokinetic Rationale
Eperisone is rapidly absorbed (Tmax = 1.6 hours) and rapidly eliminated (t½ = 1.87 hours) 6. This pharmacokinetic profile supports three-times-daily dosing and explains the lack of accumulation risk, making it safer than many traditional muscle relaxants in vulnerable populations. The drug's mechanism involves P2X7 receptor antagonism 10, providing both muscle relaxation and pain relief without significant CNS sedation 3.